MPT Product Candidate
We are collaborating with Orion Biotechnology to evaluate the compatibility and stability of Orion’s novel CCR5 antagonist, OB-002, in Phexxi with the goal of developing a Multipurpose Prevention Technology (MPT) product candidate for indications including the prevention of human immunodeficiency virus (HIV) in women. This collaboration will focus on determining compatibility and stability of OB-002 in Phexxi. Assuming positive results of this initial preclinical work, Evofem and Orion will seek government and philanthropic funding for subsequent clinical trials of the MPT product candidate.
These products have not been approved for marketing by the U.S. Food and Drug Administration or any other regulatory agency.